The Future of
Antibody Therapy Starts Here
AI-driven drug discovery meets function-first antibody selection to deliver better, faster breakthroughs.
COMMITMENT TO OUR PATIENTS
With decades of hands on experience with the numerous problems and pitfalls around antibody drugs and their discovery, OCMS is committed to getting the best possible antibody therapeutic drug to patients. OCMS aims to bring safer, more efficacious and more convenient medicines to all.
PROBLEM
The antibody industry lacks the tools to efficiently analyze every possible candidate. This leads to ‘passable’ drugs that suffer from limitations in dosing, administration, safety and efficacy.
Solution
OCMS rapidly discovers novel, de-risked, fast-follower, best-in-class antibodies with a tunable target product profile optimized for binding, immunogenicity, stability, and function.
News
OCMS Bio Appoints Pavel Nikitin as Chief Development Officer to Drive Preclinical Pipeline
Dr. Nikitin bringing extensive experience in biopharmaceutical development.
OCMS Bio Selected to Present at Biotech Showcase JPM 2025
The company’s selection at Biotech Showcase provides a powerful platform to showcase its latest advancements.
OCMS Bio Showcases AI-Driven Antibody Discovery at Antibody Engineering & Therapeutics 2024
Dr. Ramdev Puligedda presented groundbreaking research at Antibody Engineering & Therapeutics 2024, highlighting the company’s innovative use of artificial intelligence (AI) in monoclonal antibody discovery.
OCMS Bio Expands Operations with New Facility at 3700 Horizon Drive
OCMS Bio's expansion to a new state-of-the-art facility in King of Prussia boosts our antibody research and preclinical pipeline.